Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors

Abeles, Aryeh M.; Nicolescu, Mirela Sidonia; Pinchover, Zachary; Abeles, Moshe

doi:10.1177/1708538113502648

Cited by 5 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAO is uncommon globally, with an unknown cause and epidemiology [3]. There is no standardized treatment method other than avoidance of tobacco exposure [4]. Angiogenesis is one of the approved therapies for TAO in individuals with and without critical limb ischemia [5].…”

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of Transcriptome Profiles in Patients with Thromboangiitis Obliterans

Öztan,

Bozbuğa,

İşsever

et al. 2023

Genes

View full text Add to dashboard Cite

Background: Thromboangiitis obliterans (TAO) causes vascular insufficiency due to chronic inflammation and abrupt thrombosis of the medium and small arteries of the extremities. In our study, we aimed to determine biomarkers for the diagnosis of TAO by evaluating 15 male TAO patients with Shinoya diagnostic criteria and 5 healthy controls who did not have TAO-related symptoms in their family histories. Methods: The Clariom D Affymetrix platform was used to conduct microarray analysis on total RNA extracted from whole blood. A total of 477 genes (FC ≤ 5 or >5) common to the fifteen patient and five control samples were selected using comparative microarray analysis; among them, 79 genes were upregulated and 398 genes were downregulated. Results: According to FC ≤ 10 or >10, in the same TAO patient and control group, 13 genes out of 28 were upregulated, whereas 15 genes were downregulated. The 11 key genes identified according to their mean log2FC values were PLP2, RPL27A, CCL4, FMNL1, EGR1, EIF4A1, RPL9, LAMP2, RNF149, EIF4G2, and DGKZ. The genes were ranked according to their relative expression as follows: FMNL1 > RNF149 > RPL27A > EIF4G2 > EIF4A1 > LAMP2 > EGR1 > PLP2 > DGKZ > RPL9 > CCL4. Using protein–protein interaction network analysis, RPL9, RPL27A, and RPL32 were found to be closely related to EIF4G2 and EIF4A1. The Reactome pathway found pathways linked to 28 genes. These pathways included the immune system, cellular responses to stress, cytokine signaling in the immune system, and signaling by ROBO receptors. Conclusions: By figuring out the protein expression levels of the genes that have been found to explain how TAO disease works at the molecular level, it will be possible to figure out how well these chosen transcripts can diagnose and predict the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of Transcriptome Profiles in Patients with Thromboangiitis Obliterans

Öztan,

Bozbuğa,

İşsever

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

“…The former include the use of prostanoids, anticoagulants, platelet antiaggregants, nonsteroidal anti-inflammatory drugs, fibrinolytics, calcium agonists, and hemorheologic agents (13). Prostanoids, such as Iloprost and PGE1, are widely used and data show a better outcome with Iloprost versus aspirin (6,18).Surgical revascularization is not an option in most cases because of the diffuse segmental involvement (19).…”

mentioning

confidence: 99%

Spinal Cord Stimulation in Buerger’s Disease – A Case Report

Santos¹

2019

PMCR

View full text Add to dashboard Cite

Buerger’s disease (BD) or thromboangeitis obliterants is a nonatherosclerotic segmental inflammation of the medium- and small-size arteries and vessels of the extremities. The pathogenesis of this process remains unclear. This disease is typically seen in male smokers under 45 years of age, and successful therapy is possible only with abstinence from tobacco. Methods to control ischemic pain include nonpharmacological and pharmacological options, such as prostanoids, or surgical intervention (sympathectomy or revascularization). This case report describes an unusual case of Buerger’s disease in a 60-year-old woman with a moderate smoking habit. Despite apparent tobacco abstinence and therapeutic optimization, there was no clinical improvement in this patient with pharmacological treatment. Attending to the imminent risk of amputation of her fingers, spinal cord stimulation (SCS) system implantation was the chosen therapeutic option. Transcutaneous oxygen pressure (TcPO2) was measured at different points in time after implantation and there was a significant increment of TcPO2 in both hands. In fact, the patient reported no pain after the first month of spinal stimulation; analgesics were progressively reduced and complete healing of ulcers was achieved. Furthermore, the patient reported a substantial improvement in her quality of life and total functional recovery in her hands mobilization after 6 months of treatment. The Brief Pain Inventory Scale and EuroQol- 5D scale were used to evaluate disease progression and its impact on quality of life. SCS system implantation is considered a safe procedure and cost-effective in the long term. The mechanisms behind these effects are still unknown, but SCS is a promising treatment option. More studies that include larger numbers of patients are needed. Key words: Buerger, tobacco, ischemia, amputation, electrical spinal cord stimulation, transcutaneous oxygen pressure

show abstract

Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications

Chen,

et al. 2023

Thrombosis Research

View full text Add to dashboard Cite

Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors

Cited by 5 publications

References 12 publications

Comparative Analysis of Transcriptome Profiles in Patients with Thromboangiitis Obliterans

Comparative Analysis of Transcriptome Profiles in Patients with Thromboangiitis Obliterans

Spinal Cord Stimulation in Buerger’s Disease – A Case Report

Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications

Contact Info

Product

Resources

About